Topic: biotech

Billionaire Family Offices Invest in Healthcare and Biotech Startups in August

09/03/2026, 05:37 AM business growth biotech healthcare

Investment firms associated with ultra-wealthy families are significantly contributing to the resurgence of venture capital in the biotechnology sector, indicating a strong interest in innovative healthcare solutions.

BioCryst Pharmaceuticals CEO Charlie Gayer Plans Expansion into Rare Disease Drug Development Following Profitability

08/28/2026, 04:37 AM business growth biotech

BioCryst Pharmaceuticals is leveraging its recent profitability to expand its portfolio in the rare disease sector by acquiring new treatments, aiming to fill a gap left by larger pharmaceutical companies.

Analysts Ritholtz Wealth Management highlight Merck & Co., Inc. (MRK) and Amgen (AMGN) as biotech stocks show significant breakout potential

08/24/2026, 08:38 AM investing review Analysts: analysts, Ritholtz biotech

Merck's recent Phase 3 trial success in combination therapy has significantly boosted its stock, indicating a positive shift in investor sentiment towards its pipeline. This development, along with Amgen's strong performance, highlights a broader resurgence in the biotech sector, which could attract more investor interest.

Analysts Wells Fargo, Leerink Partners, and Guggenheim Initiate Coverage of Scribe Therapeutics (SCTX) with Target Prices Indicating Significant Upside Potential

08/18/2026, 07:36 AM investing rating_growth Analysts: analysts, Wells Fargo, Guggenheim, Leerink Partners biotech

Analysts are optimistic about Scribe Therapeutics' growth potential following its recent IPO, with price targets suggesting significant upside for investors. The company's innovative gene-editing technologies position it favorably in the competitive biotech landscape.

Analysts JPMorgan upgraded Charles River Laboratories (CRL) to overweight and raised target price to $310, expecting 19% upside

08/06/2026, 06:41 AM investing rating_growth Analysts: analysts, JPMorgan biotech

JPMorgan has upgraded Charles River Laboratories to overweight, raising its price target significantly, as the company benefits from a resurgence in biotechnology investments and strong quarterly earnings.

Analysts Ritholtz Wealth Management highlight Incyte (INCY) and Biogen (BIIB) as top biotech stocks reaching significant highs this summer

08/03/2026, 08:39 AM investing review Analysts: analysts, Ritholtz biotech

Incyte and Biogen are showing significant stock performance improvements, highlighting a positive trend in the biotech sector that investors should consider.

Stocks Making Significant Moves Midday: ASML, SK Hynix, SAP, Forte Biosciences, and More

07/27/2026, 10:38 AM business review software biotech

Several companies experienced significant stock movements, with ASML declining due to competition from Chinese chipmakers, while Forte Biosciences surged following an acquisition announcement. These developments highlight the ongoing volatility in the semiconductor and biotech sectors, which could impact investor sentiment and market dynamics.

Biotech Sector Remains Attractive to Investors Following Significant Recovery

07/22/2026, 01:37 PM investing review biotech healthcare

Investors in the biotechnology sector are maintaining a positive outlook following significant gains this year, driven by factors such as potential mergers and acquisitions and a recovery in clinical trials. The performance of key ETFs and specific companies, like Revolution Medicines, highlights the sector's resilience and growth potential.

Axiom Biosciences Plans to List in Hong Kong Before U.S. IPO Amid Changing Biotech Landscape

07/21/2026, 05:37 PM economy announcement biotech

Axiom Biosciences plans to go public in Hong Kong in 2027, marking a significant shift as it seeks to tap into Asia's biotech investment landscape, which has become increasingly attractive amid a challenging fundraising environment in the U.S.

Samsung Biologics to Acquire PolyPeptide Group for $1.8 Billion in Cash

07/19/2026, 07:31 PM announcement biotech

Samsung Biologics has announced a significant all-cash acquisition of PolyPeptide Group for $1.8 billion, marking a historic deal in South Korea's biopharmaceutical sector. This move aims to enhance Samsung's portfolio in the rapidly growing peptide therapeutics market, particularly in obesity treatments.